Guangzhou and London – May 22, 2025 – Bio-Thera Solutions,Ltd (688177:SH), a commercial-stage biopharmaceutical company developing apipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC,along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announcedtha...
DetailsGUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions (SHA: 688177), a commercial-stage biopharmaceuticalcompany, today announced that the China National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for BAT1706, a proposed biosimilar to Avastin® (be...
GUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions, a commercial-stage biopharmaceutical company, today announced that the Phase III clinical trial comparing the safety and efficacy of BAT1706 versus Avastin® 1 (bevacizumab) met its primary endpoint. BAT1706 is being developed by Bio-Thera So...
GUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions, Ltd., a fully-integrated pharmaceutical company, today announced that QLETLI ® (格乐立 ® ), a biosimilar to Humira ® (adalimumab), is now available in China. QLETLI ® (格乐立 ® ), the first adalimumab biosimilar approved by the Chi...
